{
    "organizations": [],
    "uuid": "007366bab8bb26162ace5f36825f06da7e763bbc",
    "author": "",
    "url": "https://www.reuters.com/article/brief-akcea-initiates-phase-2b-study-of/brief-akcea-initiates-phase-2b-study-of-hypertriglyceridemia-and-established-heart-disease-treatment-idUSFWN1P010Q",
    "ord_in_thread": 0,
    "title": "BRIEF-Akcea Initiates Phase 2b Study Of Hypertriglyceridemia And Established Heart Disease Treatment",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 25 PM / in 9 minutes BRIEF-Akcea Initiates Phase 2b Study Of Hypertriglyceridemia And Established Heart Disease Treatment Reuters Staff \nJan 5 (Reuters) - Akcea Therapeutics Inc: \n* AKCEA INITIATES PHASE 2B STUDY OF AKCEA-APOCIII-LRX IN PATIENTS WITH HYPERTRIGLYCERIDEMIA AND ESTABLISHED CARDIOVASCULAR DISEASE \n* AKCEA THERAPEUTICS INC - ‍ ANTICIPATES REPORTING TOP-LINE DATA FROM PHASE 2B OF AKCEA-APOCIII-L(RX)​ STUDY IN 2019 Source text for Eikon: Further company coverage:",
    "published": "2018-01-05T23:24:00.000+02:00",
    "crawled": "2018-01-05T23:36:27.016+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "initiate",
        "phase",
        "2b",
        "study",
        "hypertriglyceridemia",
        "established",
        "heart",
        "disease",
        "treatment",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "akcea",
        "therapeutic",
        "inc",
        "akcea",
        "initiate",
        "phase",
        "2b",
        "study",
        "patient",
        "hypertriglyceridemia",
        "established",
        "cardiovascular",
        "disease",
        "akcea",
        "therapeutic",
        "inc",
        "anticipates",
        "reporting",
        "data",
        "phase",
        "2b",
        "rx",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}